Toledo, OH – May 19, 2015 – NAMSA, the world’s leading medical research organization, is pleased to announce the approval of construction of a new state-of-the-art preclinical medical device laboratory in Shanghai, China.
This preclinical facility in China will strengthen and expand NAMSA’s MRO®Approach, offering dedicated testing capabilities for the Chinese and Asia-Pacific markets in addition to an already successful global footprint in the US, Germany, UK, France and Japan. With regulatory experts already on the ground in China readily available to guide you through preclinical testing, clinical research and post market products and services, NAMSA is able to support clients through every product development phase. By building this state-of-the-art preclinical facility in China, NAMSA will be able to support early stage research and development activities for the fastest growing medical device market in the world.
“NAMSA is pleased to offer preclinical laboratory services in China that support our existing world-class global services and strengthen the overall value to our clients,” said Yan Cai, Director, NAMSA China Laboratory Operations. “Having laboratory operations within China, paired with our strong relationships with the CFDA, will undoubtedly increase the speed to market for our Chinese clients. With unparalleled experience, our leadership in translational research focuses on insightful solutions that optimize study designs with customized support to meet the specific needs of our clients.”
Yan Cai joined NAMSA in 2014 as the Director of NAMSA’s China Laboratory Operations and will be responsible for leading the construction efforts of the new lab and setting up operations once completed. Yan has extensive industry experience. She most recently worked with Medicilon/MPI Preclinical Research, where she planned, directed and coordinated GLP lab operations with a staff of over 60 employees. She has been involved in scientific and regulatory consulting, client management and business development for pharmaceutical industry. Yan is a Certified Toxicologist through the Chinese Society of Toxicology (C.T.C.S.T). She obtained her Ph.D. in Toxicology from the Shanghai Institute of Material Medica, Chinese Academy of Sciences and holds a BS in Biochemistry from China Pharmaceutical University, Nanjing, China.
Construction of NAMSA’s new preclinical research facility in Shanghai began in May of 2015.
For further information about NAMSA or this news release, please reach out to us at namsa.com/contact-us.